These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 18356135)

  • 1. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.
    Beer TM; Smith DC; Hussain A; Alonso M; Wang J; Giurescu M; Roth K; Wang Y
    Br J Cancer; 2012 Aug; 107(5):808-13. PubMed ID: 22850553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Case of Metastatic Prostate Cancer with Neuroendocrine Differentiation with Long-Term Survival after Multidisciplinary Therapy].
    Fujita K; Kato M; Kosugi Y; Sekido Y; Matsui N; Masuda K; Yamamoto S; Matsue T; Iguchi K; Yukimatsu N; Otoshi T; Yamasaki T; Kuratsukuri K; Kohashi K; Uchida J
    Hinyokika Kiyo; 2024 Jun; 70(6):173-177. PubMed ID: 38967030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial.
    Finelli A; Beer TM; Chowdhury S; Evans CP; Fizazi K; Higano CS; Kim J; Martin L; Saad F; Saarela O
    JAMA Netw Open; 2021 Jun; 4(6):e2112426. PubMed ID: 34129025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim and end-treatment
    García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
    Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
    Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
    Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
    Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Jang HS; Koo KC; Cho KS; Chung BH
    Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.
    Evangelista L; Bertoldo F; Boccardo F; Conti G; Menchi I; Mungai F; Ricardi U; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1546-62. PubMed ID: 26956538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
    Gillessen S; Omlin A; Attard G; de Bono JS; Efstathiou E; Fizazi K; Halabi S; Nelson PS; Sartor O; Smith MR; Soule HR; Akaza H; Beer TM; Beltran H; Chinnaiyan AM; Daugaard G; Davis ID; De Santis M; Drake CG; Eeles RA; Fanti S; Gleave ME; Heidenreich A; Hussain M; James ND; Lecouvet FE; Logothetis CJ; Mastris K; Nilsson S; Oh WK; Olmos D; Padhani AR; Parker C; Rubin MA; Schalken JA; Scher HI; Sella A; Shore ND; Small EJ; Sternberg CN; Suzuki H; Sweeney CJ; Tannock IF; Tombal B
    Ann Oncol; 2015 Aug; 26(8):1589-604. PubMed ID: 26041764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictor of survival following docetaxel-based chemotherapy.
    Lee HY; Wu WJ; Huang CH; Chou YH; Huang CN; Lee YC; Yang KF; Lee MH; Huang SP
    Oncol Lett; 2014 Oct; 8(4):1788-1792. PubMed ID: 25202411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
    Han KS; Hong SJ
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients.
    Kita Y; Shimizu Y; Inoue T; Kamba T; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2013 Aug; 18(4):718-23. PubMed ID: 22791141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
    Armstrong AJ; Eisenberger MA; Halabi S; Oudard S; Nanus DM; Petrylak DP; Sartor AO; Scher HI
    Eur Urol; 2012 Mar; 61(3):549-59. PubMed ID: 22099611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
    Francini F; Pascucci A; Francini E; Bargagli G; Conca R; Licchetta A; Roviello G; Martellucci I; Chiriacò G; Miano ST; Marzocca G; Manganelli A; Ponchietti R; Savelli V; Petrioli R
    Prostate Cancer; 2011; 2011():258689. PubMed ID: 22096653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The postchemotherapy PSA surge syndrome.
    Thuret R; Massard C; Gross-Goupil M; Escudier B; Di Palma M; Bossi A; de Crevoisier R; Chauchereau A; Fizazi K
    Ann Oncol; 2008 Jul; 19(7):1308-1311. PubMed ID: 18356135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.